EOLS
Price
$12.20
Change
+$0.21 (+1.75%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
846.82M
40 days until earnings call
EVOK
Price
$2.61
Change
-$0.14 (-5.09%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
5.17M
Ad is loading...

EOLS vs EVOK

Header iconEOLS vs EVOK Comparison
Open Charts EOLS vs EVOKBanner chart's image
Evolus
Price$12.20
Change+$0.21 (+1.75%)
Volume$18.68K
Capitalization846.82M
Evoke Pharma
Price$2.61
Change-$0.14 (-5.09%)
Volume$415
Capitalization5.17M
EOLS vs EVOK Comparison Chart
Loading...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EOLS vs. EVOK commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EOLS is a StrongBuy and EVOK is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (EOLS: $11.99 vs. EVOK: $2.75)
Brand notoriety: EOLS and EVOK are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EOLS: 83% vs. EVOK: 2%
Market capitalization -- EOLS: $846.82M vs. EVOK: $5.17M
EOLS [@Pharmaceuticals: Other] is valued at $846.82M. EVOK’s [@Pharmaceuticals: Other] market capitalization is $5.17M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EOLS’s FA Score shows that 0 FA rating(s) are green whileEVOK’s FA Score has 0 green FA rating(s).

  • EOLS’s FA Score: 0 green, 5 red.
  • EVOK’s FA Score: 0 green, 5 red.
According to our system of comparison, EVOK is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EOLS’s TA Score shows that 5 TA indicator(s) are bullish while EVOK’s TA Score has 3 bullish TA indicator(s).

  • EOLS’s TA Score: 5 bullish, 5 bearish.
  • EVOK’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, EOLS is a better buy in the short-term than EVOK.

Price Growth

EOLS (@Pharmaceuticals: Other) experienced а -3.54% price change this week, while EVOK (@Pharmaceuticals: Other) price change was -2.14% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.45%. For the same industry, the average monthly price growth was -0.08%, and the average quarterly price growth was -9.41%.

Reported Earning Dates

EOLS is expected to report earnings on May 13, 2025.

EVOK is expected to report earnings on Nov 08, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (-1.45% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EOLS($847M) has a higher market cap than EVOK($5.17M). EOLS YTD gains are higher at: 8.605 vs. EVOK (-37.783). EVOK has higher annual earnings (EBITDA): -7.29M vs. EOLS (-41.81M). EOLS has more cash in the bank: 62.8M vs. EVOK (4.74M). EVOK has less debt than EOLS: EVOK (5M) vs EOLS (127M). EOLS has higher revenues than EVOK: EOLS (202M) vs EVOK (5.18M).
EOLSEVOKEOLS / EVOK
Capitalization847M5.17M16,380%
EBITDA-41.81M-7.29M573%
Gain YTD8.605-37.783-23%
P/E RatioN/AN/A-
Revenue202M5.18M3,899%
Total Cash62.8M4.74M1,325%
Total Debt127M5M2,540%
FUNDAMENTALS RATINGS
EOLS vs EVOK: Fundamental Ratings
EOLS
EVOK
OUTLOOK RATING
1..100
591
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
40
Fair valued
PROFIT vs RISK RATING
1..100
62100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6395
P/E GROWTH RATING
1..100
10074
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EVOK's Valuation (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for EOLS (94) in the Pharmaceuticals Major industry. This means that EVOK’s stock grew somewhat faster than EOLS’s over the last 12 months.

EOLS's Profit vs Risk Rating (62) in the Pharmaceuticals Major industry is somewhat better than the same rating for EVOK (100) in the Pharmaceuticals Other industry. This means that EOLS’s stock grew somewhat faster than EVOK’s over the last 12 months.

EOLS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as EVOK (100) in the Pharmaceuticals Other industry. This means that EOLS’s stock grew similarly to EVOK’s over the last 12 months.

EOLS's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as EVOK (95) in the Pharmaceuticals Other industry. This means that EOLS’s stock grew similarly to EVOK’s over the last 12 months.

EVOK's P/E Growth Rating (74) in the Pharmaceuticals Other industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that EVOK’s stock grew similarly to EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EOLSEVOK
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 17 days ago
82%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GRZZX5.72N/A
N/A
Leuthold Grizzly Short Fund
WLCAX13.53N/A
N/A
Allspring Large Company Value A
PKSCX35.59N/A
N/A
Virtus KAR Small-Cap Core C
JHERX19.40N/A
N/A
JHancock Equity Income C
HBLFX14.47N/A
N/A
Hartford Balanced Income F

EOLS and

Correlation & Price change

A.I.dvisor tells us that EOLS and RDHL have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EOLS and RDHL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
-0.33%
RDHL - EOLS
30%
Poorly correlated
-4.14%
ACET - EOLS
26%
Poorly correlated
-2.65%
EVOK - EOLS
26%
Poorly correlated
N/A
SNDL - EOLS
25%
Poorly correlated
+2.13%
LFCR - EOLS
23%
Poorly correlated
-0.14%
More

EVOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVOK has been loosely correlated with RDHL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if EVOK jumps, then RDHL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVOK
1D Price
Change %
EVOK100%
N/A
RDHL - EVOK
33%
Loosely correlated
-4.14%
NBIX - EVOK
28%
Poorly correlated
-3.25%
EOLS - EVOK
26%
Poorly correlated
-0.33%
SIGA - EVOK
25%
Poorly correlated
N/A
PRFX - EVOK
25%
Poorly correlated
+3.70%
More